Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Robert Radtke

Physician Assistant, Medical Chicago, IL Physician Assistant

NPI 1619512019 CMS profile 10959871

2418 N Ashland Ave, Chicago, IL 60614

Open in the dashboard

General payments

$6,630

268 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Radtke of Chicago, IL is reported in the CMS Open Payments database as having received $6,630 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,561 59
2024 General $1,975 75
2023 General $1,919 88
2022 General $1,175 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Radtke
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Robert Radtke were reported at $1,561. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Robert Radtke Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $1,175 $185 $55–$649 $149
2023 $1,919 $199 $58–$717 $160
2024 $1,975 $206 $62–$740 $164
2025 $1,561 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,618 63 payments
  2. Supernus Pharmaceuticals, Inc. $778 25 payments
  3. Novo Nordisk Inc $606 29 payments
  4. ViiV Healthcare Company $402 13 payments
  5. Gilead Sciences, Inc. $367 11 payments
  6. Pfizer Inc. $334 16 payments
  7. Lilly USA, LLC $316 11 payments
  8. Corium, Inc. $285 15 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $171 8 payments
  10. Tris Pharma Inc $169 9 payments
  11. Other $1,585 68 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,544 266 payments
  2. Education $86 2 payments
Products named General payments · program years 2022–2025
  1. VRAYLAR Neuroscience $696 29 payments
  2. Qelbree Viloxazine Hydrochloride $525 10 payments
  3. UBRELVY $344 16 payments
  4. APRETUDE $322 10 payments
  5. Azstarys $285 15 payments
  6. NURTEC ODT $258 13 payments
  7. QELBREE Psychology $254 15 payments
  8. VRAYLAR Neuroscience $248 7 payments
  9. Ozempic $243 12 payments
  10. RYBELSUS $243 12 payments
  11. Other $3,844 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record